ArticleInternational journal of nanomedicine2025
FOLR1-Targeted Oxygen-Delivering Nanosomes Enhance Chemo-Induced Apoptosis in Hypoxic Cancer.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Understanding the Interplay Between Obesity and Cancer: From Mechanisms to Therapeutic Opportunities.Cancers · 2026Review
- Triple-remodeling of tumor microenvironment through hyaluronidase-assisted folate-targeted lipid nanoparticle-mediated siVEGF/siPD-L1 for enhanced tumor immunotherapy.Journal of translational medicine · 2026Article
- From Barrier to Gateway: Nanomaterials Reshaping the Tumor Microenvironment for Therapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The rapid proliferation of tumor cells increases oxygen demand, while the underdeveloped vasculature limits supply, leading to hypoxia in the tumor microenvironment. This hypoxic condition is a hallmark of solid tumors and contributes to tumor progression, immune suppression, metastasis, and resistance to therapy. Purpose: This study aimed to counteract tumor hypoxia and improve therapeutic outcomes by delivering both oxygen and the chemotherapeutic agent doxorubicin directly to tumors. Methods: HON_FA@DOX, a folate-functionalized and perfluorohexane-enhanced liposomal nanosome co-loaded with oxygen and doxorubicin, was developed and characterized based on its physical properties. Its tumor-targeting capability, oxygen delivery efficiency, and therapeutic potential were evaluated under in vitro conditions. Cellular experiments were conducted to assess selective binding, hypoxia modulation, cytotoxicity, and the expression of genes related to apoptosis. Results: HON_FA@DOX exhibited a doxorubicin encapsulation efficiency of 36.6% and an enhanced oxygen loading capacity of 23.2 mg/L. The nanosomes demonstrated selective binding to FOLR1-expressing tumor cells and sustained release of doxorubicin. This dual-delivery system effectively alleviated hypoxia within the tumor microenvironment and reduced the expression of the hypoxia-related gene HIF-1α by 50%. Furthermore, HON_FA@DOX treatment significantly increased the expression of apoptosis-related genes and mitigated chemotherapy resistance, thereby enhancing the overall anticancer efficacy. Conclusion: We demonstrated that multifunctional nanosomes delivering both oxygen and doxorubicin effectively alleviated tumor hypoxia and reduced chemotherapy resistance, thereby enhancing anticancer efficacy. This approach presents a promising strategy for addressing tumor hypoxia and may be broadly applicable as an adjunct to conventional cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.